中国实用眼科杂志
中國實用眼科雜誌
중국실용안과잡지
CHINESE JOURNAL OF PRACTICAL OPHTHALMOLOGY
2009年
9期
1021-1025
,共5页
玻璃体视网膜疾病%Densiron68%眼内填充
玻璃體視網膜疾病%Densiron68%眼內填充
파리체시망막질병%Densiron68%안내전충
Vitrectomy%Demiron68%Endotamponade
目的 探讨Demiron68作为玻璃体腔填充物治疗玻璃体视网膜疾病的有效性及安全性.方法 对18例19只眼玻璃体视网膜疾病患者入选,年龄在19～78岁,平均年龄(47.63±21.93)岁,术前术后常规行视力、眼压的测定,眼前后段检查、OCT、角膜内皮镜及B超等检查.手术方式包括:Densiron68填充术及硅油取出术.Densiron68的充填时间是44～141d,平均(76±23.84)d.取油后的随访时间为40～197d,平均(95.74±44.58)d.结果 取油后,16只眼(84.21%)达到稳固的视网膜复位效果,1例患者(5.26%)在Densiron 68充填第12d时出现了复发性视网膜脱离,2例(10.53%)取油后出现复发性视网膜脱离;术后视力较术前改善14只眼(73.68%);术后OCT检测黄斑区各层形态结构基本正常,神经上皮层未见萎缩、变薄等现象;角膜内皮细胞计数术前、填充术后1月与取油术后1月比较无显著差异(P>0.05);术后并发症主要有短暂的前房反应、硅油乳化、晶体后囊膜混浊、术后一过性高眼压和瞳孔阻滞性青光眼.结论 Densiron68作为玻璃体视网膜疾病的眼内填充物,可以明显提高患者视网膜的解剖复位率和视力,并对角膜内皮细胞和黄斑区神经上皮层无不良影响.虽然其填充后短期内并发症发生率较高,但不影响手术后的视网膜解剖复位率和视力提高.
目的 探討Demiron68作為玻璃體腔填充物治療玻璃體視網膜疾病的有效性及安全性.方法 對18例19隻眼玻璃體視網膜疾病患者入選,年齡在19～78歲,平均年齡(47.63±21.93)歲,術前術後常規行視力、眼壓的測定,眼前後段檢查、OCT、角膜內皮鏡及B超等檢查.手術方式包括:Densiron68填充術及硅油取齣術.Densiron68的充填時間是44～141d,平均(76±23.84)d.取油後的隨訪時間為40～197d,平均(95.74±44.58)d.結果 取油後,16隻眼(84.21%)達到穩固的視網膜複位效果,1例患者(5.26%)在Densiron 68充填第12d時齣現瞭複髮性視網膜脫離,2例(10.53%)取油後齣現複髮性視網膜脫離;術後視力較術前改善14隻眼(73.68%);術後OCT檢測黃斑區各層形態結構基本正常,神經上皮層未見萎縮、變薄等現象;角膜內皮細胞計數術前、填充術後1月與取油術後1月比較無顯著差異(P>0.05);術後併髮癥主要有短暫的前房反應、硅油乳化、晶體後囊膜混濁、術後一過性高眼壓和瞳孔阻滯性青光眼.結論 Densiron68作為玻璃體視網膜疾病的眼內填充物,可以明顯提高患者視網膜的解剖複位率和視力,併對角膜內皮細胞和黃斑區神經上皮層無不良影響.雖然其填充後短期內併髮癥髮生率較高,但不影響手術後的視網膜解剖複位率和視力提高.
목적 탐토Demiron68작위파리체강전충물치료파리체시망막질병적유효성급안전성.방법 대18례19지안파리체시망막질병환자입선,년령재19～78세,평균년령(47.63±21.93)세,술전술후상규행시력、안압적측정,안전후단검사、OCT、각막내피경급B초등검사.수술방식포괄:Densiron68전충술급규유취출술.Densiron68적충전시간시44～141d,평균(76±23.84)d.취유후적수방시간위40～197d,평균(95.74±44.58)d.결과 취유후,16지안(84.21%)체도은고적시망막복위효과,1례환자(5.26%)재Densiron 68충전제12d시출현료복발성시망막탈리,2례(10.53%)취유후출현복발성시망막탈리;술후시력교술전개선14지안(73.68%);술후OCT검측황반구각층형태결구기본정상,신경상피층미견위축、변박등현상;각막내피세포계수술전、전충술후1월여취유술후1월비교무현저차이(P>0.05);술후병발증주요유단잠적전방반응、규유유화、정체후낭막혼탁、술후일과성고안압화동공조체성청광안.결론 Densiron68작위파리체시망막질병적안내전충물,가이명현제고환자시망막적해부복위솔화시력,병대각막내피세포화황반구신경상피층무불량영향.수연기전충후단기내병발증발생솔교고,단불영향수술후적시망막해부복위솔화시력제고.
Objective To evaluate the efficacy and security after using densiron 68 as an endotamponade in the vitrectomy.Methods Nineteen eyes of 18 patients aged 19 to 85 years old with vitreoretinopathy were included.Initial evaluation included present ophthalmologic and general medical history, determination of the best corrected visual acuity, intraocular pressure (IOP) measurement by non-contact tonometer, detailed slit lamp and fundus examination, OCT examination, corneal endothelium examination.Surgery was performed as a standard three-port, pars plana vitrectomy.At removal surgery, 15 cases of the posterior poles discussion was performed.Mean duration of the Densiron68 endotamponade was 76±23.84 days.Results After Densiron68 removal, 16 patients (84.21%) showed a stable reattached retinal without further interventions, while, in 1 patient (5.26%), recurrent retinal redetachment appeared during endotamponade.Two patients (10.53%) developed redetachment after Densiron68 removal.Visual acuity was improved in 14 eyes (73.68%). Postoperative measurement of the macular by optical coherence tomography was normal.The thickness of the neuroepithelial layer showed no apparent changes.The postoperative corneal endothelium cell showed no significant changes.Compared with the preoperatives, no statistically significant differences (P>0.05).Side effect included temporary inflammatory reaction, posterior capsular opacification, silicon oil emulsification, temporary intraocular pressure and pupillary block glaucoma.Conelusiens The results showed that densiron68 as an endotamponade was efficacy and security.
